生物活性

• 描述NBI-98854 is a potent, highly selective, VMAT2 inhibitor that is effective in regulating the levels of dopamine release during nerve communication.
• 临床研究

• NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
  NCT02581865	Tourette Syndrome	Phase 2	Completed	-	-
  NCT02679079	Tourette Syndrome	Phase 2	Completed	-	-
  NCT03698331	Tardive Dyskinesia (TD)	Phase 4	Recruiting	April 2019	United States, California ... more >> Neurocrine Clinical Site Recruiting Anaheim, California, United States, 92804 Neurocrine Clinical Site Recruiting Glendale, California, United States, 91206 Neurocrine Clinical Site Recruiting Norwalk, California, United States, 90650 Neurocrine Clinical Site Recruiting Oceanside, California, United States, 92054 Neurocrine Clinical Site Recruiting San Bernardino, California, United States, 92108 United States, Florida Neurocrine Clinical Site Recruiting Hialeah, Florida, United States, 33012 Neurocrine Clinical Site Recruiting Hialeah, Florida, United States, 33013 Neurocrine Clinical Site Recruiting Hialeah, Florida, United States, 33018 United States, Hawaii Neurocrine Clinical Site Recruiting Honolulu, Hawaii, United States, 96817 United States, Michigan Neurocrine Clinical Site Recruiting Ann Arbor, Michigan, United States, 48105 United States, Ohio Neurocrine Clinical Site Recruiting Beechwood, Ohio, United States, 44122 United States, Oklahoma Neurocrine Clinical Site Recruiting Oklahoma City, Oklahoma, United States, 73112 United States, Pennsylvania Neurocrine Clinical Site Recruiting Scranton, Pennsylvania, United States, 18503 United States, Texas Neurocrine Clinical Site Recruiting DeSoto, Texas, United States, 75115 Neurocrine Clinical Site Recruiting Irving, Texas, United States, 75062 Puerto Rico Neurocrine Clinical Site Recruiting San Juan, Puerto Rico, 00926 Collapse <<

• 更多
• 参考文献

• [1] Grigoriadis DE, Smith E, et al. Pharmacologic Characterization of Valbenazine (NBI-98854) and Its Metabolites. J Pharmacol Exp Ther. 2017 Jun;361(3):454-461.

  [2] O'Brien CF, Jimenez R, et al. NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study. Mov Disord. 2015 Oct;30(12):1681-7.